Advertisement

3 Results

for author "Sofie Peirs"

Type a term to search within all articles in this journal: e.g., stem cell
Citation
Citation-specific search information
e.g., 2009
e.g., 20
e.g., 3
e.g., 29
e.g., 10.9999/123XYZ456
Authors, Keywords
Search for specific authors and/or words and phrases.
e.g., Smith, JS
e.g., Smith, JS
Type any phrase that appears in the article title
Type any phrase that appears within article title or abstract
Type any phrase that appears within article body, title or abstract
e.g., Smith, JS
Book publisher name
Limit Results
Limit search results by date
Date of Publication
e.g., 2017-01-23
e.g., 2017-01-23
Format Results
  • Oncogenic ZEB2 Activation Drives Sensitivity Towards LSD1 Inhibition in T-Cell Acute Lymphoblastic Leukemia
    Steven Goossens, Sofie Peirs, Geert Berx, Pieter Van Vlierberghe, Jody J. Haigh
    Oncogenic ZEB2 Activation Drives Sensitivity Towards LSD1 Inhibition in T-Cell Acute Lymphoblastic Leukemia ~~~
  • Oncogenic ZEB2 activation drives sensitivity towards KDM1A inhibition in T-cell acute lymphoblastic leukemia
    Steven Goossens, Sofie Peirs, Wouter Van Loocke, Jueqiong Wang, Mina Takawy, Filip Matthijssens, Stefan E. Sonderegger, Katharina Haigh, Thao Nguyen, Niels Vandamme, Magdaline Costa, Catherine Carmichael, Filip Van Nieuwerburgh, Dieter Deforce, Oded Kleifeld, David J. Curtis, Geert Berx, Pieter Van Vlierberghe, Jody J. Haigh
    Oncogenic ZEB2 activation drives sensitivity towards KDM1A inhibition in T-cell acute lymphoblastic leukemia ~~~
  • ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia
    Sofie Peirs, Filip Matthijssens, Steven Goossens, Inge Van de Walle, Katia Ruggero, Charles E. de Bock, Sandrine Degryse, Kirsten Canté-Barrett, Delphine Briot, Emmanuelle Clappier, Tim Lammens, Barbara De Moerloose, Yves Benoit, Bruce Poppe, Jules P. Meijerink, Jan Cools, Jean Soulier, Terence H. Rabbitts, Tom Taghon, Frank Speleman, Pieter Van Vlierberghe
    ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia ~~~